NRAS, NRAS, Which Mutation Is Fairest of Them All?

Christine Grill; Lionel Larue

doi:10.1016/j.jid.2016.06.011

NRAS, NRAS, Which Mutation Is Fairest of Them All?

J Invest Dermatol. 2016 Oct;136(10):1936-1938. doi: 10.1016/j.jid.2016.06.011.

Authors

Christine Grill¹, Lionel Larue²

Affiliations

¹ Institut Curie, Paris Sciences et Lettres Research University, Institut National de la Santé et de la Recherche Médicale U1021, Normal and Pathological Development of Melanocytes, Orsay, France; Université Paris-Sud, Université Paris-Saclay, Centre National de la Recherche Scientifique Unité Mixte de Recherche 3347, Orsay, France; Equipe Labellisée Ligue Contre le Cancer, Orsay, France.
² Institut Curie, Paris Sciences et Lettres Research University, Institut National de la Santé et de la Recherche Médicale U1021, Normal and Pathological Development of Melanocytes, Orsay, France; Université Paris-Sud, Université Paris-Saclay, Centre National de la Recherche Scientifique Unité Mixte de Recherche 3347, Orsay, France; Equipe Labellisée Ligue Contre le Cancer, Orsay, France. Electronic address: lionel.larue@curie.fr.

PMID: 27664710
DOI: 10.1016/j.jid.2016.06.011

Abstract

In 28% of melanomas, NRAS is mutated in one of two hotspots: G12 or Q61. Phosphoproteomic analysis of primary human melanocytes transduced with G12 and Q61 showed different phosphorylation events in the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Surprisingly, NRAS(G12) modulates the PI3K pathway and overexpresses the kinase PIM2, whereas NRAS(Q61) is associated with the MAPK pathway and overexpression of CK2α.

Publication types

Comment

MeSH terms

Humans
Melanocytes
Melanoma / genetics*
Mitogen-Activated Protein Kinases / genetics
Mutation
Phosphatidylinositol 3-Kinases / genetics*
Proto-Oncogene Proteins B-raf / genetics

Substances

Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinases